Summary
Introduction Leishmaniasis is a disease caused by parasites of the genus Leishmania. In Colombia, 6 pathogenic species have been reported. Traditional parasitological diagnosis based on the observation of parasites does not allow the species to be identified, which is why biochemical or molecular methods must be used, including conventional PCR, but this has some limitations and requires long periods of time to obtain results., which are sometimes inconclusive.
General Objective Implement a methodology based on PCR-HRM, which allows the simultaneous detection and identification of parasites of the Leishmania genus in clinical samples from patients or parasites in cultures.
Materials and methods A PCR-HRM was standardized, through which 237 clinical samples were evaluated, 98 classified as positive and 139 as parasitologically negative by direct and/or culture. The typings were compared with a previously standardized PCR-RFLP.
Results It was possible to implement a PCR-HRM for the diagnosis and identification of Leishmania species, obtaining 100% agreement with the typings obtained by PCR-RFLP. It was even possible to detect and identify the parasite in samples diagnosed as negative by conventional methods. It was found that, with a reliability percentage greater than 95%, 91 samples out of 98 were typed, of which 81.63% of the cases were L. panamensis, 11.22% were L. braziliensis and 7.14 were indeterminate.% of cases.
Conclusions PCR-HRM is a good method that allows the identification of the most prevalent species in Colombia, comparing specific mean denaturation temperatures according to the Leishmania species involved.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by resources from the PECET group and the University of Antioquia, Colombia.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work was approved by the ethics committee of the SIU-University Research Headquarters
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available from the authors upon reasonable request. All data produced in the present work are contained in the manuscript.
